BBI - Brickell/Kaken' sofpironium bromide gel Ok'd in Japan

Brickell Biotech (BBI) +8% in premarket, after its development partner, Kaken Pharmaceutical received approval to sofpironium bromide gel, 5% under the brand name ECCLOCK in Japan, for the treatment of primary axillary hyperhidrosis (abnormally excessive sweating in underarms)Under the sublicense agreement with Kaken, Brickell will receive sales-based milestone and tiered royalties payments. Kaken has rights to develop and commercialize sofpironium bromide in Korea, China and certain other Asian countries.Brickell is on track to initiate its Phase 3 program in the U.S. for sofpironium bromide gel, 15% during the next quarter. The study will include two Phase 3 trials to evaluate the product compared to vehicle in ~350 subjects (per trial) with primary axillary hyperhidrosis.

For further details see:

Brickell/Kaken' sofpironium bromide gel Ok'd in Japan